Chemotherapy of bronchial carcinoma.
D000818:Animals; D000963:Antimetabolites / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D001772:Blood Cell Count; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000517:prevention & control; D001984:Bronchial Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004195:Disease Models, Animal; D004338:Drug Combinations; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D010996:Pleural Effusion / Q000150:complications / Q000188:drug therapy; D011379:Prognosis; D014652:Vascular Diseases / Q000209:etiology; D014683:Vena Cava, Superior; D014750:Vincristine / Q000627:therapeutic use
D000963:Antimetabolites; D000970:Antineoplastic Agents; D004338:Drug Combinations; D014750:Vincristine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate